Indication
In adults for the treatment of chronic kidney disease (CKD).
Medicine details
- Medicine name:
- dapagliflozin (Forxiga)
- SMC ID:
- SMC2763
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Abbreviated
- Publication due date:
- 07 April 2025